The myNEO neoantigen prediction platform focuses on detecting, identifying, and validating all alterations that have occurred in cells, and what their immunogenic impact is. The most effectual process wherein a cell undergoes genomic, transcriptomic, and epigenomic changes is during oncogenesis. Identifying per patient which alterations lay at the origin of the cancer cells and which have been accumulated during clonal expansion of the tumour is of high importance. Studying these alterations, their impact on the presented antigen repertoire on the cell’s surface, and the immunogenic implications has several important applications.

Find out how we can be your partner for highly accurate neoantigen predicion, target discovery or personalised patient classification into treatment groups

Contact us